Voyager Therapeutics, Inc.

Voyager Therapeutics (VYGR) reported one officer departure via 8-K filing on April 21, 2026, with no cyber incidents detected over the past 90 days. A single leadership change in a biotech firm warrants context around timing, role criticality, and any concurrent financing or capital structure shifts that may have prompted the departure. The full $49 Report extends analysis to a 12-month lookback, calculates dilution risk scores tied to any recent equity raises, and flags AI-detected risk signals in executive stability and cash runway that 8-K filings alone do not surface.